1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > AstraZeneca PLC - Strategy and SWOT Report

AstraZeneca PLC - Strategy and SWOT Report

  • November 2015
  • -
  • MarketLine
  • -
  • 43 pages

Introduction

AstraZeneca PLC - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on AstraZeneca PLC required for business and competitor intelligence needs

- A study of the major internal and external factors affecting AstraZeneca PLC in the form of a SWOT analysis

- An in-depth view of the business model of AstraZeneca PLC including a breakdown and examination of key business segments

- Intelligence on AstraZeneca PLC’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about AstraZeneca PLC, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

AstraZeneca (or 'the company'), a UK-based global biopharmaceutical company, is engaged in developing, manufacturing and marketing prescription pharmaceuticals in several therapeutic areas. The company primarily operates in the Americas, Europe and Asia. It is headquartered in London, the UK, and employed about 57,500 people as on December 31, 2014. The company recorded revenues of $26,095 million during the financial year ended December 2014 (FY2014), an increase of 1.5% over FY2013. The operating profit of the company was $2,137 million in FY2014, a decrease of 42.4% compared with FY2013. The net profit of the company was $1,233 million in FY2014, a decrease of 51.8% compared with FY2013.

Reasons to Purchase:

- Gain understanding of AstraZeneca PLC and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess AstraZeneca PLC as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on AstraZeneca PLC’s business structure, strategy and prospects

Table Of Contents

AstraZeneca PLC - Strategy and SWOT Report
Company Overview
Business Description
History
Key Employees and Biographies
Company View
Locations and Subsidiaries
SWOT Analysis
Revenue Analysis
Key Competitors
Major Products and Services

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.